Biophytis S.A.

DB:6XB3 Stock Report

Market Cap: €2.2m

Biophytis Management

Management criteria checks 4/4

Biophytis' CEO is Stanislas Veillet, appointed in May 2015, has a tenure of 9.67 years. total yearly compensation is €349.00K, comprised of 71.6% salary and 28.4% bonuses, including company stock and options. directly owns 0.9% of the company’s shares, worth €19.92K. The average tenure of the management team and the board of directors is 5.3 years and 5.3 years respectively.

Key information

Stanislas Veillet

Chief executive officer

€349.0k

Total compensation

CEO salary percentage71.6%
CEO tenure9.7yrs
CEO ownership0.9%
Management average tenure5.3yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Stanislas Veillet's remuneration changed compared to Biophytis's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€15m

Mar 31 2024n/an/a

-€16m

Dec 31 2023€349k€250k

-€17m

Sep 30 2023n/an/a

-€18m

Jun 30 2023n/an/a

-€20m

Mar 31 2023n/an/a

-€22m

Dec 31 2022€428k€250k

-€24m

Sep 30 2022n/an/a

-€27m

Jun 30 2022n/an/a

-€30m

Mar 31 2022n/an/a

-€31m

Dec 31 2021€460k€250k

-€31m

Sep 30 2021n/an/a

-€28m

Jun 30 2021n/an/a

-€25m

Mar 31 2021n/an/a

-€25m

Dec 31 2020€374k€250k

-€26m

Sep 30 2020n/an/a

-€24m

Jun 30 2020n/an/a

-€22m

Mar 31 2020n/an/a

-€22m

Dec 31 2019€310k€250k

-€19m

Sep 30 2019n/an/a

-€19m

Jun 30 2019n/an/a

-€18m

Mar 31 2019n/an/a

-€15m

Dec 31 2018€295k€225k

-€14m

Compensation vs Market: Stanislas's total compensation ($USD361.40K) is about average for companies of similar size in the German market ($USD464.61K).

Compensation vs Earnings: Stanislas's compensation has been consistent with company performance over the past year.

CEO

Stanislas Veillet (59 yo)

9.7yrs

Tenure

€349,000

Compensation

Mr. Stanislas Veillet, Ph D., serves as Chairman of the Board and Chief Executive Officer of Biophytis SA since May 22, 2015. Mr. Veillet is the Co-founder of Biophytis (created in 2006) and served as its...

Leadership Team

NamePositionTenureCompensationOwnership
Stanislas Veillet
Chairman of the Board & CEO9.7yrs€349.00k0.90%
€ 19.9k
Waly Dioh
Chief Clinical Operating Officer5.3yrsno data0.0060%
€ 133.3
Pierre Dilda
Chief Scientific Officer5.3yrsno data0.0032%
€ 69.8
Rene Lafont
Scientific Advisor & Member of Scientific Advisory Board5.3yrsno datano data
Rob van Maanen
Chief Medical Officer3.3yrsno data0%
€ 0
Edouard Bieth
Chief Business Officer1.3yrsno datano data
Chiara Baccelli
Chief Pharmaceutical Operations Officer & Quality Assurance Director2yrsno data0%
€ 0
_ Teylan
Financial Controllerno datano datano data

5.3yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 6XB3's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stanislas Veillet
Chairman of the Board & CEO9.7yrs€349.00k0.90%
€ 19.9k
Rene Lafont
Scientific Advisor & Member of Scientific Advisory Board5.3yrsno datano data
Claude Allary
Independent Director3.5yrs€25.00k0%
€ 0
Jose-Alain Sahel
Member of Scientific Advisory Boardno datano datano data
Thomas Voit
Member of Scientific Advisory Board7.3yrsno datano data
Roger Fielding
Member of Scientific Advisory Board8.7yrsno datano data
Jean Mariani
Chairman of Scientific Advisory Board & Director8.8yrs€25.00k0%
€ 0
Nadine Coulm
Independent Director9.7yrs€25.00k0.000060%
€ 1.3
Yann Meunier
Member of Scientific Advisory Board1.2yrsno datano data
Bernard Levy
Member of Scientific Advisory Board1.2yrsno datano data
Dennis Villareal
Member of Scientific Advisory Boardless than a yearno datano data
Francisco Guarner
Member of Scientific Advisory Boardless than a yearno datano data

5.3yrs

Average Tenure

69yo

Average Age

Experienced Board: 6XB3's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 03:26
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biophytis S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuH.C. Wainwright & Co.
Thomas GuillotKepler Cheuvreux